CU24064B1 - Derivados de 1h-imidazo-[4,5-c]-quinolinona - Google Patents

Derivados de 1h-imidazo-[4,5-c]-quinolinona

Info

Publication number
CU24064B1
CU24064B1 CU2011000221A CU20110221A CU24064B1 CU 24064 B1 CU24064 B1 CU 24064B1 CU 2011000221 A CU2011000221 A CU 2011000221A CU 20110221 A CU20110221 A CU 20110221A CU 24064 B1 CU24064 B1 CU 24064B1
Authority
CU
Cuba
Prior art keywords
imidazo
derivatives
treatment
diseases
quinolinone
Prior art date
Application number
CU2011000221A
Other languages
English (en)
Other versions
CU20110221A7 (es
Inventor
Pascal Furet
Frank Stephan Kalthoff
Robert Mah
Christian Ragot
Frédéric Stauffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697442&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20110221A7 publication Critical patent/CU20110221A7/es
Publication of CU24064B1 publication Critical patent/CU24064B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere al uso de derivados de 1H-imidazo-[4,5-c]-quinolinona y de las sales de los mismos en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido y para la elaboración de las preparaciones farmacéuticas para el tratamiento de estas enfermedades: a los derivados de 1H-imidazo-[4,5-c]-quinolinona para utilizarse en el tratamiento de las enfermedades dependientes de la cinasa de proteína o de lípido: a un método para el tratamiento contra estas enfermedades, el cual comprende administrar los derivados de 1H-imidazo-[4,5-c]-quinolinona a un animal de sangre caliente, en especial a un ser humano: a las preparaciones farmacéuticas que comprenden un derivado de 1H-imidazo-[4,5-c]-quinolinona, en especial para el tratamiento de una enfermedad dependiente de la cinasa de proteína y/o de lípido: a los derivados 1H-imidazo-[4,5-c]-quinolinona novedosos: y a un proceso para la preparación de los derivados de 1H-imidazo-[4,5-c]-quinolinona novedosos.
CU2011000221A 2009-06-04 2011-11-30 Derivados de 1h-imidazo-[4,5-c]-quinolinona CU24064B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18414109P 2009-06-04 2009-06-04
PCT/EP2010/057719 WO2010139731A1 (en) 2009-06-04 2010-06-02 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES

Publications (2)

Publication Number Publication Date
CU20110221A7 CU20110221A7 (es) 2012-03-15
CU24064B1 true CU24064B1 (es) 2014-12-26

Family

ID=42697442

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000221A CU24064B1 (es) 2009-06-04 2011-11-30 Derivados de 1h-imidazo-[4,5-c]-quinolinona

Country Status (30)

Country Link
US (2) US8476294B2 (es)
EP (1) EP2438064A1 (es)
JP (1) JP5596137B2 (es)
KR (1) KR101445458B1 (es)
CN (1) CN102574845B (es)
AR (1) AR076949A1 (es)
AU (1) AU2010255727B2 (es)
BR (1) BRPI1010621A2 (es)
CA (1) CA2763821A1 (es)
CL (1) CL2011003052A1 (es)
CO (1) CO6470887A2 (es)
CR (1) CR20110608A (es)
CU (1) CU24064B1 (es)
DO (1) DOP2011000373A (es)
EA (1) EA020715B1 (es)
EC (1) ECSP11011500A (es)
GE (1) GEP20156267B (es)
IL (1) IL216452A0 (es)
MA (1) MA33332B1 (es)
MX (1) MX2011012943A (es)
NI (1) NI201100209A (es)
NZ (1) NZ596487A (es)
PE (1) PE20120224A1 (es)
SG (1) SG176572A1 (es)
TN (1) TN2011000626A1 (es)
TW (1) TWI464168B (es)
UA (1) UA106074C2 (es)
UY (1) UY32682A (es)
WO (1) WO2010139731A1 (es)
ZA (1) ZA201108439B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010035744A1 (de) 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
BR112013013837A2 (pt) * 2010-12-06 2016-09-13 Piramal Entpr Ltd derivados de substituição de imidazoquinolina
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
WO2013071698A1 (zh) * 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
WO2014141118A1 (en) * 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
CN105121411B (zh) 2013-04-15 2017-10-10 杜邦公司 杀真菌酰胺
US9893299B2 (en) 2013-09-11 2018-02-13 Merck Patent Gmbh Heterocyclic compounds
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
JP6606428B2 (ja) * 2013-10-11 2019-11-13 国立大学法人 東京医科歯科大学 脊髄小脳変性症を予防又は治療するための薬剤
AU2014352463B2 (en) * 2013-11-20 2017-05-11 Beijing Forelandpharma Co. Ltd. Ketone derivatives of imidazoles, pharmaceutical combinations and uses thereof
NO2714752T3 (es) 2014-05-08 2018-04-21
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EP3277681B1 (de) 2015-04-02 2019-05-08 Merck Patent GmbH Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
GB201519568D0 (en) * 2015-11-05 2015-12-23 Astrazeneca Ab Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
CN110023312A (zh) 2016-10-13 2019-07-16 由卫生与公众服务部部长代表的美利坚合众国 阻止疟疾寄生虫传播的化合物和方法
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
JOP20190209A1 (ar) * 2017-03-16 2019-09-12 Astrazeneca Ab مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
JP7569688B2 (ja) 2017-12-22 2024-10-18 ハイバーセル，インコーポレイテッド ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体
TW202112767A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
CN116574099A (zh) * 2019-09-23 2023-08-11 南京征祥医药有限公司 磷酸二酯酶抑制剂及用途
CA3184212C (en) * 2020-09-21 2024-11-05 Wei Zhong 1-(3,3-DIFLUOROPIPERIDIN-4-YL)-IMIDAZO[4,5-C]QUINOLEIN-2-ONE SUBSTITUTE COMPOUNDS WITH THE ABILITY TO CROSS THE BLOOD-BRAIN BARRIER
CN115136336A (zh) * 2021-01-26 2022-09-30 京东方科技集团股份有限公司 量子点发光器件、显示装置和制作方法
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
CN117384154A (zh) * 2023-09-04 2024-01-12 广州医科大学 一种吡咯并喹啉酮化合物、合成方法及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AU2005284835A1 (en) 2004-09-14 2006-03-23 Novartis Vaccines And Diagnostics Inc. Imidazoquinoline compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
ES2429170T3 (es) 2005-11-04 2013-11-13 3M Innovative Properties Company 1H-Imidazoquinolinas sustituidas con hidroxilo y alcoxilo y métodos
GEP20125436B (en) 2006-11-20 2012-03-26 Novartis Ag Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
RU2481838C2 (ru) * 2007-07-24 2013-05-20 Новартис Аг Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr
US20090082387A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched nvp-bez234
CA2925257C (en) 2008-03-26 2019-04-30 Carlos Garcia-Echeverria 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes
US20110212053A1 (en) 2008-06-19 2011-09-01 Dapeng Qian Phosphatidylinositol 3 kinase inhibitors
EP2356120B1 (en) * 2008-09-30 2016-10-12 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions

Also Published As

Publication number Publication date
EP2438064A1 (en) 2012-04-11
MX2011012943A (es) 2012-01-27
AU2010255727A1 (en) 2011-12-08
CA2763821A1 (en) 2010-12-09
JP5596137B2 (ja) 2014-09-24
CO6470887A2 (es) 2012-06-29
CN102574845B (zh) 2015-09-02
JP2012528828A (ja) 2012-11-15
IL216452A0 (en) 2012-01-31
AR076949A1 (es) 2011-07-20
EA020715B1 (ru) 2015-01-30
CR20110608A (es) 2012-01-16
US20100317657A1 (en) 2010-12-16
ZA201108439B (en) 2012-08-29
TWI464168B (zh) 2014-12-11
UA106074C2 (uk) 2014-07-25
KR20120034710A (ko) 2012-04-12
WO2010139731A1 (en) 2010-12-09
US20140005163A1 (en) 2014-01-02
TN2011000626A1 (en) 2013-05-24
CU20110221A7 (es) 2012-03-15
CL2011003052A1 (es) 2012-08-31
NZ596487A (en) 2012-11-30
ECSP11011500A (es) 2012-01-31
SG176572A1 (en) 2012-01-30
US8476294B2 (en) 2013-07-02
KR101445458B1 (ko) 2014-10-07
CN102574845A (zh) 2012-07-11
MA33332B1 (fr) 2012-06-01
TW201102386A (en) 2011-01-16
NI201100209A (es) 2012-02-02
GEP20156267B (en) 2015-04-14
PE20120224A1 (es) 2012-04-04
AU2010255727B2 (en) 2013-02-28
DOP2011000373A (es) 2011-12-31
UY32682A (es) 2011-01-31
EA201101704A1 (ru) 2012-07-30
BRPI1010621A2 (pt) 2016-06-21

Similar Documents

Publication Publication Date Title
CU20110221A7 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
BRPI0416796A (pt) compostos orgánicos
CR9994A (es) Vacuna terapéutica
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
CU20100062A7 (es) Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteínas quinasas b
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
MX374724B (es) Derivados de carbazol.
AR104068A1 (es) Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
DOP2005000051A (es) Oxadiazolonas, procedimientos para su preparacion y su uso como productos farmaceuticos
CY1114251T1 (el) Χρηση ενος συνδυασμου ο οποιος περιλαμβανει l-kapnitinh ή αλκανοϋλ l-kapnitinh, λιποδιαλυτη βενζοκινονη και ωμεγα-3-πολυακορεστο λιπαρο οξυ για την παρασκευη ενος διαιτητικου συμπληρωματος ή φαρμακου για τη θεραπευτικη αγωγη παθησεων του κερατοειδους
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
UY29846A1 (es) N-(1,3,4)-tiadiazol-2-il-bencensulfonamidas, procesos para su preparación y su uso como productos farmacéuticos
PA8596701A1 (es) Derivados de aminoacidos sustituidos con cicloalquilo, procedimiento para su preparacion y su uso como medicamentos
CY1110021T1 (el) ΔΙΑΡΩΜΑΤΙΚΕΣ ΕΝΩΣΕΙΣ ΟΙ ΟΠΟΙΕΣ ΕΝΕΡΓΟΠΟΙΟΥΝ ΥΠΟΔΟΧΕΙΣ ΤΟΥ ΤΥΠΟΥ PPARγ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΑΥΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΚΟΣΜΗΤΙΚΗ Ή ΣΕ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ
UY29848A1 (es) (1,3,4)-tiadiazol-2-il-amidas bicíclicas del ácido aril-sulfónico, procesos para su preparación y su uso como productos farmacéuticos
CU23842B1 (es) Derivados de n5-(2-etoxi-etil)-n3-(2-piridinil)-3,5-piperidin-dicarboxamida
ECSP055984A (es) Derivados cicloalquilo que tienen grupos ácido carboxílico bioisostéricos, procesos para su preparación y su uso como composiciones farmacéuticas
AR061357A1 (es) Preparaciones de combinacion que comprenden bifeprunox y l- dopa
AR061355A1 (es) Preparaciones de combinacion que comprenden slv308 y l-dopa

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)